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Abstract 
Purpose: The purpose of this study was to investigate the effects of a yearlong exercise 
intervention compared to usual care on cardiorespiratory fitness in sedentary breast cancer 
survivors who were taking aromatase inhibitors and experiencing arthralgia. Methods:   
Participants were randomized to either an exercise intervention group that met twice weekly with 
a personal trainer or usual care.  Participants completed self-administered questionnaires, 
including reporting demographic and personal characteristics, and a graded treadmill test using a 
modified Branching protocol at baseline and at the end of the 12-month study.  T-tests and χ2 
analyses were used to assess change in cardiorespiratory fitness, measured by VO2max, over the 
12 month study period. Potential modifiers of change in cardiorespiratory fitness were examined, 
these included, disease and treatment characteristics, BMI, and age, Results: The average age of 
the sample was 63.3 years (SD± 6.2) and women had been taking an AI for an average of 2 
years. A majority of women were diagnosed with Stage I breast cancer (54%) and received 
treatment after surgery of radiation and/or chemotherapy (92%). The average percent change in 
VO2max was 5.28 ml/kg/min among exercisers compared to negligible change (0.14 ml/kg/min) 
among the usual care group (p=0.094). No effect modification was observed among the a priori 
variables; however, a stratified analysis revealed similar trends among age strata, baseline BMI 
and fitness levels, as well as stage and treatment groups. Conclusion: In this study, an exercise 
intervention including a combination of strength training and aerobic exercise was effective in 
improving cardiorespiratory fitness among previously sedentary breast cancer survivors taking 
aromatase inhibitors. These results are encouraging for post-menopausal women who are 
recommended to take AIs to reduce their risk of cardiovascular and all-cause mortality. 
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Background  
Breast cancer is the most frequently diagnosed cancer in women, and accounted for 23% 
(1.38 million) of total new cancer cases and 14% (458,400) of the total cancer deaths in 2011.1 
Approximately two-thirds of women with this malignancy are diagnosed with estrogen-receptor 
positive tumors.2 This type of breast cancer is treated with endocrine therapy to prevent cancer 
recurrence and improve survival. Until the early 2000s, tamoxifen had been the mainstay of 
endocrine therapy for pre- and post-menopausal women; recently though, several large 
randomized clinical trials have revealed aromatase inhibitors (AI) as a superior treatment option 
for postmenopausal women, demonstrating greater disease-free survival, time to recurrence, and 
overall survival, compared with tamoxifen.3  
The American Society of Clinical Oncology guidelines recommend that AIs be used as 
adjuvant endocrine therapy in postmenopausal women with Stage I-III hormone receptor-
positive breast cancer, either as initial monotherapy or after 2-5 years of tamoxifen therapy.3 
Currently, there are three third-generation AIs that have been approved by the FDA for adjuvant 
therapy in postmenopausal women with hormone receptor-positive, early stage breast cancer: 
anastrozole, letrozole and exemestane. AIs prevent the peripheral conversion of androgens into 
estradiol, thus lowering circulating estrogen to below detectable levels. Exemestane, a steroidal 
drug, binds irreversibly to the aromatase enzyme, and the nonsteroidal drugs, letrozole and 
anastrozole, reversibly bind to the aromatase enzyme. All 3 drugs are used widely at this time.3 
While AIs are now regarded as the standard of care for adjuvant therapy of hormone 
receptor positive breast cancer in postmenopausal women, there remains concern regarding the 
toxicity of these drugs. Cumulative results indicate that arthralgia, defined as pain or stiffness in 
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the joints, is one of the major adverse events associated with AI therapy, and has been reported 
in up to 50% of patients, and the most common reason for drug discontinuation4 Arthralgia has 
been observed among patients treated with both steroidal (exemestane) and non-steroidal 
(anastrozole and letrozole) AIs. Spontaneous symptom resolution is rare during therapy, but 
common after cessation of AI treatment. 
Other concerns of AI treatment include their adverse effects on bone health and 
metabolism, endocrine related quality of life, cognitive ability, and cardiovascular disease (CVD) 
risk.4,5,6,7Of note, CVD mortality is more common among breast cancer survivors than breast 
cancer-related mortality. 8 
 Elevated risk of CVD is likely in part due to low levels of circulating endogenous 
estrogens caused by AI treatment, resulting in the loss of estrogenic protection.9 Jones, et al 
(2007), proposed the “Multiple Hit Hypothesis”, which described a heightened risk of 
cardiovascular disease among women diagnosed with early breast cancer:  preexisting risk 
factors, such as age, menopause status, and previous chronic disease are compounded by the 
varying degrees of cardiovascular insults from adjuvant therapies, resulting in an overall greater 
susceptibility to cardiovascular events among women diagnosed with breast cancer.10 A recent 
meta-analysis of randomized trials found that the risk of grade 3 and 4 cardiovascular adverse 
events was statistically significantly greater among postmenopausal women receiving AI 
treatment compared to the risk of women receiving tamoxifen (tamoxifen is a selective estrogen 
receptor modulator, thus not decreasing estrogen levels similarly to the AIs).11 Moreover, Bell et 
al (2011) described notable adverse changes in lipid levels (total cholesterol, lipoproteins, and 
triglycerides) after 3 months of treatment with exemestane and letrozole, serving as surrogate 
measures of long-term cardiovascular risk.  
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Cardiorespiratory fitness is an important, yet underused prognostic measure in clinical 
and research settings. Peak, or maximal, oxygen uptake (VO2max) is the gold standard of 
measuring cardiorespiratory fitness, and can be determined by the amount of oxygen inhaled and 
carbon dioxide exhaled.12 This objective measure is obtained through incremental 
cardiorespiratory exercise (e.g. treadmill walking or bicycle ergometer) to exhaustion or 
symptom limitation. Studies have demonstrated the association between cardiorespiratory fitness 
and all-cause mortality and cardiovascular events in healthy individuals.7,1314 A recent meta-
analysis, conducted by Kodama and colleagues (2009), found that among healthy men and 
women, the relative risk of all-cause mortality and CVD events were lowered by 13% and 15%, 
respectively, per 1-MET increase level of VO2max  (RR = 0.87 (95%CI: 0.84-0.90) and 0.85 
(95%CI: 0.82-0.88), respectively).7 Similarly, recent evidence indicates VO2max provides 
critical information for predicting cancer-related pre- and post-operative health outcomes and 
understanding cancer-therapy induced cardiac effects.15,1617,18,19  In cross-sectional studies, a 
notable lower level of VO2max, measured at diagnosis, has been observed among lung and breast 
cancer patients, consistently ~30% lower than that of age- and sex-matched sedentary individuals 
without a history of cancer2021 The fitness level of these patients remained significantly lower or 
became even further reduced if no exercise interventions were introduced. In a recent meta-
analysis, Fong and colleagues reviewed 10 exercise interventions on VO2max conducted in 
women diagnosed with breast cancer and found, those randomized to exercise, compared with 
control, experienced an increased peak oxygen consumption (2.2mL/kg/min, 1.0-3.4,p<0.01) and 
peak power output (21.0W, 13.0 to 29.1, p<0.01). This improvement in VO2max is encouraging 
in regards to improving physical quality of life as well as decreasing CVD risk. However, none 
of the studies published included a high CVD risk sample of women taking AIs. To our 
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knowledge there are no studies that focus on the specific effects of exercise on CVD outcomes 
among patients taking an AI.  Thus, the purpose of this study was to examine the effect of a 1-
year exercise intervention compared to usual care on cardiorespiratory fitness in 50 
postmenopausal women diagnosed with hormone-receptor positive breast cancer who have been 
taking an AI for at least 6 months. 
 
Materials and Methods 
Study Population 
 The aim of the Hormone and Physical Exercise (HOPE) study was to examine, in 121 
postmenopausal breast cancer survivors who have been taking an AI for at least 6 months and are 
experiencing at least mild arthalgia originating during AI treatment, the yearlong effect of 
exercise compared to usual care on toxic side effects of AI use, namely arthalgia, bone mass, and 
endocrine-related quality of life.  Women diagnosed with Stage I-IIIC breast cancer were eligible 
for the study. Participants must have been taking an AI for at least 6 months and be currently 
experiencing side effects of the medication (i.e., at least mild arthralgia, defined as > 3 on the 
Brief Pain Inventory (BPI) Short Form Questionnaire22).  
 To observe a maximal effect from the exercise intervention, only women reporting less 
than 90 min/wk of moderate-to-vigorous intensity aerobic exercise and no strength training in the 
previous year were eligible to participate.  
Recruitment 
  The Rapid Case Ascertainment (RCA) Shared Resource Service of the Yale Cancer Center 
was used to obtain names of women diagnosed with hormone receptor positive breast cancer 
who were treated at one of four hospitals in CT: Smilow Cancer Hospital at Yale-New Haven, 
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St. Raphael’s Hospital, Bridgeport Hospital, and Greenwich Hospital. The RCA provides the 
primary investigator with the potential participants’ names and their physician’s name. Initial 
contact was made with the physician to request permission to contact the participant regarding 
the study. If approved, the participant was mailed an invitation letter, describing the study and 
informing her of the next steps of the study recruitment and enrollment process (i.e., screening 
telephone call). If at the screening telephone call the participant was deemed eligible and 
interested, she was scheduled for a baseline visit. 
 Between April 1, 2010 and December 31, 2012, we completed 1020 screening telephone 
calls. Of the 1020 women screened, 664 were ineligible, 235 were not interested. The remaining 
12% (n = 121) were enrolled in the study and subsequently randomized to the intervention 
(n=60) or usual care group (n=61). Of these 121 women, 50 completed 12- months of the study 
as of March 31, 2013, and are included in the analyses (See Figure 1). 
 
Data Collection 
At the baseline visit, participants completed questionnaires regarding medical history and health 
habits, quality of life, as well as a 7-day daily activity log and physical activity questionnaire. 
Questionnaires and physical measurements (e.g. anthropometric measurements, DEXA scan, 
blood draw) were repeated during follow up clinic visits at 6 and 12 months.  Cardiorespiratory 
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Measures 
Demographics and medical history:  Information was collected via an interviewer-administered 
questionnaire at the baseline visit.  Information regarding disease stage, hormone receptor status, 
adjuvant therapy, and surgery was provided by participants and later confirmed by their 
physician and review of the medical records. 
Physical activity. At baseline, 6- and 12-months, participants completed a 7-day physical activity 
log (PAL)23 and an interviewer-administered physical activity questionnaire (PAQ)24 to assess 
physical activity at baseline and at 6 and 12 months. For the PAL, women recorded the type and 
duration of any recreational activity performed on each day. Hours per week spent in moderate-
to-vigorous intensity activity were determined using Ainsowrth’s Compendium of Physical 
Activities.25  
 
Anthropometrics. Height and weight were measured at baseline, 6 and 12 months and BMI was 
calculated. Participants were weighed in light indoor clothing, without shoes, rounding up to the 
nearest 0.1 kg; height was measured in a standard manner, without shoes, using a stadiometer, 
rounding up to the nearest 0.1 cm. All measures were performed and recorded twice in 
succession by the same technician and averaged for data entry. 
 
Cardiorespiratory Fitness: Research staff, blinded to the participant’s randomization group, 
measured each participant’s cardiorespiratory fitness at baseline and 12-months with a VO2 max 
treadmill test (including 12-lead ECG). Expired gases were analyzed using a metabolic 
measurement cart (CPX-D; Medical Graphics, St Paul, MN). Peak oxygen consumption was 
determined by taking the highest values during a 15-second period. A modified “Branching 
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Treadmill Protocol” was used: initially, participants began at a normal walking speed (3.0 MPH) 
and 0% grade, after 2 min the speed was increased to a fast walking speed (3.5 MPH) and 0% 
grade, and thereafter, only the grade was increased by 3% every 2 min. Oxygen consumption 
(VO2), carbon dioxide production (VCO2), and flow rate was be measured continuously. During 
each stage, the onsite cardiologist monitored blood pressure and heart rate, and the research staff 
measured perceived effort using the Borg scale. The test was ended when the participant 
indicated that she could not continue any further, or if the supervising physician recommended 
halting the exercise for medical concerns.  Maximal heart rate, peak exertion level, and reasons 
for stopping the test were recorded, and a report of the cardiorespiratory measures (VO2max, 
VCO2max, respiratory exchange ratio [RER], and metabolic equivalent for task [MET]) was 
obtained.  
Randomization  
Participants were randomized to either the exercise group or usual care with equal probability, 
with blocking on whether taking a bisphosphonate and whether arthralgia/joint pain started after 
initiating the AI. Those women randomized to the exercise group were scheduled for their first 
supervised exercise training session immediately. Women randomized to the usual care group 
were contacted by a trained health professional on a monthly basis to discuss relevant health 
topics so as to maintain study compliance. 
 
Exercise Intervention 
 The exercise intervention group received social and behavioral support and research staff 
contact time to encourage them to increase their exercise level to include twice weekly strength- 
training sessions and 150 min of aerobic exercise per week (e.g., three 50-min aerobic exercise 
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sessions or five 30-min sessions) over 12 months. The HOPE study trainer and participant(s) met 
at a local gym designated by the study during designated weekly times. 
 
Strength Training Sessions: Each strength training session was ~30 minutes. Seven common 
strength-training exercises were performed for three sets and 8-12 repetitions using variable 
resistance machines (e.g., leg press, leg extension, bench press, lat pull down, seated row) .26,27 
 
Aerobic Exercise Intervention: The participants were also required to do moderate- to vigorous-
intensity aerobic exercise for a total of 150 min/week (the current PA recommendation). 
Participants wore heart rate monitors during each workout, with heart rate electronically 
monitored with high/low pulse rate alarms individually set for each subject. Exercise started at 
50% of predicted maximal heart rate (220-age) and was gradually increased in accordance with 
American College of Sports Medicine guidelines to approximately 60-80% of predicted maximal 
heart rate. Following each exercise session, participants recorded the type, duration, perceived 
intensity of activity, and average heart rate during exercise in physical activity logs.  The aerobic 
exercise consisted primarily of treadmill walking, although participants could choose to meet the 
exercise goal through other forms of aerobic activity.   
Recording of Strength and Aerobic Exercise Sessions: Following each strength and aerobic 
exercise session, participants completed a physical activity log. The logs were submitted weekly 
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Usual Care 
Immediately after randomization, participants in the usual care group were provided written 
information that emphasized the importance of a healthy lifestyle. Each month, women 
randomized to usual care were contacted by a trained health professional to discuss health 
education topics relevant to women taking AIs and breast cancer survivors in general. Examples 
of topics were benefits of AIs, bone health, and lymphedema.  
Statistical Analysis   
 Participants were grouped according to the intent-to-treat approach (ITT), in which all 
participants were analyzed according to their intervention assignment at randomization, 
regardless of adherence. A sample size of 50 women had completed baseline and 12-month 
treadmill examinations at the time of this preliminary analysis. T-tests and χ2 analyses were used 
to assess between-group differences at baseline. A t-test was also used to test for significant 
differences in cardiorespiratory fitness parameters between exercise and control groups at 
baseline and 12-months. The percent change in cardiorespiratory fitness was also compared 
between groups using t-tests. P<0.05 was considered statistically significant.  
 We also explored potential effect modification by a priori variables that were potentially 
associated with change in cardiorespiratory fitness, identified based on previous studies and on 
observations of the study staff and included: treatment, disease stage, time since diagnosis, 
baseline fitness level, and baseline BMI. Intervention effects were evaluated by the differences in 
the mean percent change at 12-months between the intervention and usual care groups using the 
generalized estimating equation modification to linear regression models to account for the 
longitudinal nature of the data.    
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Adherence, assessed from weekly 7-day physical activity logs, was defined as the 
average min/week of moderate-intensity aerobic exercise performed from baseline to 12-months. 
Good adherence was defined as 80% of the exercise prescription (or 120 min of the 150 
min/week goal). For exerciser only, we examined changes in cardiorespiratory fitness by 
adherence. Statistical analyses were preformed using SAS software (version 9.3; SAS Institute 




 Baseline demographic and physiological factors for women randomized to exercise vs. 
usual care were not significantly different (Table 1). The average age of study participants was 
62.6 years. The majority of women in our sample were non-Hispanic white and highly educated; 
91.6% achieving a college degree or greater. Sixty-eight percent of the participants were 
classified as overweight (BMI>=25) at baseline (BMI= 28.45 ± 6.25). The average time since 
breast cancer diagnosis was 2.9 years and women had been taking an AI for 2 years prior to 
enrollment in the study. The majority of participants were diagnosed with Stage I breast cancer 
(54%) and received treatment after surgery (radiation and/or chemotherapy) (92%).  
 
Adherence to Exercise Intervention  
 The mean attendance rate to the twice-weekly yearlong supervised gym sessions (that 
included aerobic and resistance exercise) was 80.3%. When examining adherence to aerobic 
exercise, women participated in moderate- to vigorous-intensity aerobic exercise for 148.0 ± 
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75.17 min/week (99% of the prescribed 150 min/week).  More than half (57.7%) of the 
exercisers exceeded the goal of 150 min/week over the 12 months (Table 2).   
 
Baseline cardiorespiratory fitness by treatment group  
 The average baseline VO2max for all participants in the study was 23.45 ml/kg/min and  
did not vary by treatment group (Table 3). Vigorous-intensity exercise is defined as greater than 
6.0 metabolic equivalents (METs). The average METs achieved during the baseline 
cardiorespiratory exam among all participants was 6.71 METs. There was no significant 
difference in baseline METs (p=0.932) and peak heart rate (p=0.626) between women 
randomized to exercise vs. usual care. The average respiratory exchange ratio (RER), a 
confirmatory measure of peak oxygen uptake and a maximal test being achieved, for all 
participants was 1.09.  
 
Effect of exercise vs. usual care on VO2max   
 The average cardiorespiratory fitness level after the 12-month intervention among 
exercisers was 24.75 ml/kg/min compared to 23.50 ml/kg/min in the control group (p=0.429). 
There was a borderline statistically significant difference in percent change in cardiorespiratory 
fitness pre- and post-intervention among the exercise group (5.28 ml/kg/min) compared to that of 
the usual care group (0.14 ml/kg/min) (p=0.0944).  There were no significant differences in peak 
heart rate or peak RER among treatment groups at the 12-month assessment; however, the 
exercise group demonstrated an average 4.56% increase in METS from baseline to 12-months 
compared to a 4.85% decline in METS in the usual care group (p=0.0796).  
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Effect of exercise on cardiorespiratory fitness stratified by potential modifiers  
 Age, disease stage, treatment received, time on aromatase inhibitors, baseline body mass 
index, and baseline cardiorespiratory fitness did not modify the effect of exercise on percent 
change in cardiorespiratory fitness. However, stronger effects of exercise on percent change in 
cardiorespiratory fitness were observed among women with greater baseline BMI and lower 
baseline fitness levels (Table 4).  
 
Effect of exercise on cardiorespiratory fitness stratified by attendance 
Women who had greater attendance to gym sessions (greater than 80% attendance) 
demonstrated greater percent change in cardiorespiratory fitness (7.11%) compared to those with 
poor attendance (-0.46%, p=0.0822).  
 
Discussion 
 In our study, an exercise regime of moderate- to vigorous-intensity aerobic exercise and 
resistance training was associated with a borderline statistically significant increase in 
cardiorespiratory fitness among breast cancer survivors taking aromatase inhibitors. The HOPE 
exercise intervention protocol was feasible from the standpoint of efficacy and implementation, 
and well accepted by the participants.  
Our findings are consistent with previous research investigating exercise interventions in 
breast cancer survivors, showing a significant increase in cardiorespiratory fitness in women 
enrolled in the exercise prescription. McNeely et al (2006) concluded that participating in 
aerobic exercise during and after cancer treatment has been effective in improving functional 
capacity, as measured from symptom limiting graded exercise testing 3.39 ml/kg/min; CI: 1.67 to 
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5.1). Our results are also in accordance with the data presented in the meta-analysis performed 
by Fong and colleagues (2012), demonstrating a significant association between physical activity 
and increase peak oxygen consumption among survivors of lung, colorectal, and breast cancer 
(2.2 ml/kg/min, p<0.01).   
Whereas other studies have examined the cardiorespiratory effects of aerobic and 
resistance exercise on breast cancer survivors, only the study conducted by Rogers and 
colleagues (2009) have shown an increase in VO2max among 30 survivors taking aromatase 
inhibitors. Participants engaged in a 12-week physical activity behavior change intervention, 
which included 12 individual supervised exercise sessions and received counseling on home-
based exercise programs, The authors examined the physiological effects of exercise among 
women taking AIs for at least 8 months, but did not represent a high risk population: women did 
not report arthalgia or AI-associated side effects.  Rogers and colleagues reported a non 
significant but moderate-to-large increase in VO2max; however, cardiorespiratory fitness was 
measured using a submaximal treadmill protocol and the duration of the intervention was only 3 
months. Whereas, the HOPE study uses a maximal exercise testing protocol (modified 
Branched), which provides a more accurate estimate of peak VO2max, and measures changes in 
fitness after a yearlong exercise intervention.  
Attendance to twice-weekly resistance training sessions was 80% among exercisers.  
Approximately 92.3% of exercisers achieved 90-minutes per week of moderate- to vigorous- 
physical activity, which is 60% of the national recommendation of 150 minutes/week.  
According to ACSM guidelines, for women between the ages 60-65, a VO2max between 
23.0 and 34.0 ml/kg/min is defined as normal cardiorespiratory fitness. At baseline, the average 
VO2max among participants was 23.45 ml/kg/min, indicating relatively low fitness levels.   
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Similarly, Burnett et al (2013) reported relatively low fitness levels in a cohort of breast 
cancer survivors with a mean VO2max (25.4 ± 5.3 mL.kg-1.min-1), which was similar to the 20th 
percentile threshold value (25.1 mL.kg-1.min-1) for age and gender group matched normative 
values. Cardiorespiratory capacity is often compromised in breast cancer survivors because of 
the pathology of disease, therapeutic regimes, and subsequent weight gain and physical inactivity 
as a result of treatment.  The detrimental effects of poor cardiorespiratory fitness have been well 
documented in variety of subpopulations, particularly among cancer patients.23, 28  
A concern when conducting an incremental treadmill tests is that a participant may not 
achieve maximal oxygen uptake.  The respiratory exchange ratio (RER) is used as evidence of a 
definitive plateau of the VO2. The literature suggests a criterion value of RER between 1.0 and 
1.15 indicates maximal exertion.29 The average RER among our participants was 1.09, which 
provides evidence that maximal testing of cardiorespiratory fitness is feasible among breast 
cancer survivors.  Moreover, the average metabolic equivalents (METs) achieved for both 
treatment groups during baseline and 12-month testing was greater than 6 METs, signifying 
vigorous-intensity physical activity was achieved during the treadmill test. The exercise group 
achieved greater METs during 12-month follow-up, meaning women that participated in the 
exercise intervention were capable of performing higher intensity activity to achieve maximum 
oxygen uptake compared to the control group. METs and heart rate can be used to explain a 
woman’s functional capacity; an inability to exercise for more than 6 minutes is associated with 
an ability to increase heart rate to >85% of maximum predicated heart rate. These are significant 
indicators of increased risk of coronary events. Participants that experience an excessive rise in 
heart rate during the test and reach 85% of maximum heart rate in the beginning stages 
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demonstrate limited exercise capacity. This rapid rise is primarily a result of reduced stroke 
volume caused by physical deconditioning, cardiac disease or arrhythmias.30  
At the end of the 12-monthintervention, the average VO2max among exercisers increased 
to 24.75 ml/kg/min (%∆ = 5.28 ± 10.59); whereas women randomized to usual care 
demonstrated negligible or no change in cardiorespiratory fitness at 12-months (23.5 ml/kg/min -
± 5.34; %∆= 0.14 ± 10.73). Research in older age healthy cohorts has shown that adults can 
achieve the same 10 to 30 percent increase in VO2max in response to exercise training as their 
younger counterparts.31 Improved peak oxygen consumption after exercise training is associated 
with increase cardiac output and greater arteriovenous oxygen content difference (a-VO2 diff).32 
There is biological plausibility to suggest that this mechanism is responsible for the 
physiological changes observed in this study.  
 While we did not observe statistically significant effect modification by our a priori 
covariates, stronger effects of exercise on cardiorespiratory fitness were observed by baseline 
BMI status and fitness status. Irrespective of BMI (obese vs. not obese), women in the exercise 
group experienced a similar  improvement in cardiorespiratory fitness over the course of the 
study; however, controls with who were obese experienced a drastic decline in cardiorespiratory 
fitness (-6.36ml/kg/min ± 3.69) over the 12-month study. These results suggest that women with 
greater baseline BMI levels (≥ 30 kg/m2) can receive the greatest cardiorespiratory fitness benefit 
from a 12-month exercise protocol. Women with lower cardiorespiratory fitness at baseline 
(stratified by the median value of 24 ml/kg/min) experienced larger improvements in VO2 max 
compared to their fitter counterparts, as participating in the amount of exercise recommended 
was able to improve their VO2max. The more fit women at baseline may have needed more 
exercise to increase their V02max moreso than less fit women.  
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AIs offer an effective strategy for breast cancer survivors to reduce the risk of recurrence, 
particularly in early stage hormone-sensitive breast cancer. While AI treatment is generally well 
tolerated, it is important to consider the long-term health impacts of hormone therapy on other 
health outcomes, especially in postmenopausal women. The cardiovascular risks of estrogen 
deprivation experienced in postmenopausal women are exacerbated by endocrine therapy with 
AIs; long-term effects on the cardiovascular system are especially relevant, because CVD is a 
common cause of death among breast cancer patients.33, 34 High aerobic functional capacity has 
been associated with beneficial health outcomes, such reductions in all-cause mortality and 
cardiovascular events, and improvements in health-related quality of life.7,35As demonstrated in 
the present study, appropriate exercise protocols serve an important role in the management of 
cardiovascular risk in this population; aerobic physical activity can reverse the cardiac stresses of 
hormone therapy and previous sedentary lifestyle.7  
 Strengths of The HOPE study was its methodologically strong design, population-based 
recruitment strategy, randomization to study groups, a physical activity prescription that met 
national guidelines, detailed measurement of physical activity and adherence, gold standard 
assessment of cardiorespiratory fitness, and long study duration. However, the sample evaluated 
in these analyses is small with implications for compromised statistical power with regard to 
some stratified analyses. Our sample was predominantly non-Hispanic white and highly 
educated.   
In conclusion, there is promising evidence that supervised resistance training, coupled by 
adequate aerobic exercise, compared with usual care, is associated with improvements in 
cardiorespiratory fitness for breast cancer survivors undergoing aromatase inhibitor treatment. 
As new treatment therapies are developed and breast cancer survivorship improves, cardiac 
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health will continue as a major concern among this population as cardiovascular disease 
mortality is more common among breast cancer survivors than breast cancer-related mortality.8 
In a study of a demographically similar population of older cardiac patients, Keteylan and 
colleagues (2008) concluded that a 1 ml/kg/min improvement in VO2max is associated with 15% 
decrease risk for all-cause mortality and CVD-specific mortality demonstrating relatively small 
average changes in cardiorespiratory fitness at the population level could have great implications 
for longevity in breast cancer survivors.  
As we transition into the era of “personalized medicine” in oncology, it will be critical to 
identify exercise prescriptions that are suitable for the clinical and treatment characteristics of a 
patient subgroup. 36 Future studies examining physical activity interventions among breast cancer 
survivors will help generate guidelines for safe and efficacious exercise protocols. Moreover, 
future trials should investigate the effects of exercise on other objective CVD measures. 
Measuring B-type natiuretic peptide (BNP) and troponin T (TnT), biomarkers of cardiac injury, 
can provide more information about the effects of aromatase inhibitor on cardiovascular health 
and quantify the impact of exercise interventions on these measures.  
 
 











Mean (SD) or 
N (%) 
(n=24) 
Age (years) 63.3 ± 6.2 62.5 ± 7.1 
Ethnicity (%)   
     White (Non-Hispanic) 23 (88.5%) 21 (87.5%) 
     Black or African American 3 (11.5%) 2 (8.3%) 
    Asian or Pacific Islander (0%) 1 (4.17) 
Education (%)    
    Less than high school degree  2 (7.7%) 2 (8.3%) 
    High school diploma or GED 8 (30.8%) 8 (33.3%) 
     College graduate or professional school  16 (61.5%) 14 (58.3%) 
Weight (kg)  79.9  ± 19.0 71.73 ± 15.0 
BMI (kg/m2) 30.4 ± 7.2 26.9 ± 4.6 
Time since diagnosis (months) 36.3 ± 28.3 34.0 ± 19.9 
Time on AI (months) 23.9 ± 12.27 26.1 ± 16.0 
 Disease Stage    
     Stage I 14 (53.8%) 13 (54.2%) 
     Stage II 8 (32.0%) 7 (31.8%) 
     Stage III 3 (11.5%) 1 (4.2%) 
     Unknown 1 (3.58%) 1 (4.2%) 
Treatment after surgery    
     None 1 (3.8%) 3 (12.5%) 
     Radiation only 0 (0%) 3 (12.5%) 
     Chemotherapy only 12 (46.2%) 9 (37.5%) 
     Radiation and chemotherapy 13 (50.0%) 9 (37.5%) 
No	  statistically	  significant	  differences	  between	  exercise	  and	  usual	  care	  groups	  at	  baseline	  (p<0.05).	  	  
	  
Table 1: Baseline characteristics of randomized participants in the HOPE study 
(N=50). 
	  





Attendance to gym sessions (strength training) 80.3% ± 14.83% 
Moderate- to vigorous-intensity aerobic exercise 
(min/week)	  1  
      Mean (SD) 148.0 ± 75.17 
% of subjects adhering to   
     ≥ 150 min/week (100% of goal) 57.7% 
     ≥ 120 min/week (80% of goal) 69.2% 
     ≥ 90 min/week (60% of goal) 92.3% 
     ≥ 60 min/week (40% of goal) 96.1% 
     ≥ 30 min/week (20% of goal)  100.0% 
1	  Mean	  min/week	  of	  moderate-­‐	  to	  vigorous-­‐intensity	  aerobic	  activity	  from	  
baseline	  to	  12-­‐months	  determined	  from	  the	  Daily	  Activity	  Logs	  	  
	  
Table 2: Adherence from baseline to 12-months in HOPE study 
(n= 26) 




Mean (SD)  (n=26) 
Usual Care 




VO2max (ml/kg/min)1    
      Baseline  23.51 ± 4.78 23.38 ± 4.20 0.915 
      12-months 24.75 ± 5.74 23.50 ± 5.34 0.429 
      %∆ 5.28 ± 10.59 0.14 ± 10.73 0.0944 
Peak RER2    
     Baseline  1.09 ± 1.06 1.09 ± 0.06 0.855 
     12-months 1.09 ± 0.07 1.02 ± 0.24 0.256 
Peak HR    
     Baseline   156.60 ± 12.45 154.30 ± 19.97 0.626 
     12-months 155.9 ± 13.73 152.3 ± 19.57 0.454 
MET3     
      Baseline  6.72 ± 1.37 6.69 ± 1.22 0.932 
      12-months 6.98 ± 1.71 6.38 ± 2.04 0.285 
      %∆ 4.56 ± 10.97 -4.85 ± 22.91 0.0796 
	  
1	  Normal	  cardiorespiratory	  fitness	  is	  defined	  as	  a	  VO2max	  between	  23	  ml/kg/min	  and	  	  	  	  	  	  	  	  	  	  	  	  	  
34	  ml/kg/min.	  Low	  fitness	  levels	  is	  defined	  as	  a	  VO2max	  <	  13.	  	  
Source:	  Preventive	  Medicine	  Center,	  Palo	  Alto,	  Calif.,	  and	  a	  survey	  of	  published	  sources.	  	   	  
2	  Respiratory	  exchange	  ratio	  (RER)	  =	  (CO2	  production/	  O2	  uptake)	  serves	  as	  a	  indirect	  
measure	  of	  muscle	  oxidative	  capacity	  to	  get	  energy	  	  
3	  Metabolic	  equivalent	  (MET)	  is	  a	  unit	  used	  to	  estimate	  the	  amount	  of	  oxygen	  used	  by	  the	  
body	  during	  physical	  activity.	  Activity	  that	  burns	  3	  to	  6	  METs	  is	  considered	  moderate-­‐	  
intensity	  physical	  activity.	  Activity	  that	  burns	  greater	  than	  6	  METs	  is	  considered	  vigorous-­‐
intensity	  physical	  activity.	  	  
Table 3: Unadjusted comparison of cardiorespiratory fitness levels 
between women randomized to exercise vs. usual care in the HOPE study.  
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 %∆ VO2max P-value  
Age ≤ 63y 
    Exercisers n=14 
    Controls n=15 
Age > 63y 
    Exercisers n=12 
    Controls n=9 
 
6.22 (2.96) 











BMIb ∫< 30 kg/m2 
    Exercisers n=16 
    Controls n=18 
BMIb ≥ 30 kg/m2 
    Exercisers n=10 
















Disease Stage  
Stage I   
    Exercisers n=14 
    Controls n=13 
Stage II and III  
    Exercisers n=11 

















Time since diagnosis≤ 35 
months 
    Exercisers n=13 
    Controls n=13 
Time on since diagnosis > 35 
months 
    Exercisers n=12 


















Time on AI ≤ 23 months 
    Exercisers n=12 
    Controls n=10 
Time on AI > 23 months 
    Exercisers n=11 















VO2maxb < 24 ml/kg/min  
    Exercisers n=14 
    Controls n=11 
VO2maxb ≥ 24 ml/kg/min 
    Exercisers n=12 
    Controls n=13 
 
6.13 (2.55) 

















Table 4: Stratified analysis of change in cardiorespiratory fitness between women 
randomized to exercise vs. usual care in the HOPE study.  
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    Exercisers n=26 




Numbers may not sum to total due to missing data 
Table reflects measurements at baseline 
* P for interaction  
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Physician consent given and recruitment letter 
mailed to participant telling them we will call them 
within one week to screen 
N=1397 
 
Screened via telephone 
N=1020 




• No time (n = 77) 
• Not interested (n = 95) 
• Declined/vague reason (n = 9) 
• Hang up (n = 6) 
• Lives too far away (n = 14) 
• Unwilling/unable to participate 
in study activities (n = 22) 
• Gym too far away (n = 12) 
 









Completed 6 Months as of 2/1/13 
N= 44 
Complete 6 Months as of 2/1/13 
N= 50 
Cases ascertained from tumor registry and contacted 




Unable to contact/screen 
n = 412 
• Disconnected (n = 62) 
• Wrong number (n = 41) 
• No answer (n = 26) 
• Busy signal (n = 3) 
• Voice message (n = 280) 
 
No Physician Consent 
n =144 
• Consent declined (n =130) 




• Physical illness (n = 89) 
• Mental illness (n = 7) 
• Not feeling well (n = 7) 
• Doesn’t speak English (n = 29) 
• No transportation (n = 7) 
• Lives out of state (n = 39) 
• Too physically active (n = 86) 
• No joint pain (BPI < 3) (n = 147) 
• Not on AI (n = 253) 
 
Completed 12 Months as of 3/31/13 
N= 26 








N=1 before 6 
Months 
N = 2 after 6 
Months 
Dropped-Out 
N=3 before 6 
Months 
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